Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring SUNNYVALE, Calif., Dec. 09, ...
CeriBell (NASDAQ:CBLL) executives said the company's first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while ...
Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures SUNNYVALE, ...
Hosted on MSN
CeriBell Q1 Earnings Call Highlights
CeriBell (NASDAQ:CBLL) reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company's strongest ...
Analysts' ratings for CeriBell (NASDAQ:CBLL) over the last quarter vary from bullish to bearish, as provided by 5 analysts. In the table below, you'll find a summary of their recent ratings, revealing ...
SUNNYVALE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with ...
SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with ...
SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results